Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Depreciation and Depletion (2021 - 2025)

Kiniksa Pharmaceuticals International's Depreciation and Depletion history spans 5 years, with the latest figure at $121000.0 for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 37.5% year-over-year to $121000.0; the TTM value through Dec 2025 reached $196000.0, down 56.25%, while the annual FY2025 figure was $196000.0, 56.25% down from the prior year.
  • Depreciation and Depletion reached $121000.0 in Q4 2025 per KNSA's latest filing, up from $27000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $416000.0 in Q2 2021 to a low of $13000.0 in Q2 2025.
  • Average Depreciation and Depletion over 5 years is $219400.0, with a median of $262500.0 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: soared 64.97% in 2023, then crashed 89.08% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $376000.0 in 2021, then decreased by 21.81% to $294000.0 in 2022, then fell by 19.73% to $236000.0 in 2023, then plummeted by 62.71% to $88000.0 in 2024, then soared by 37.5% to $121000.0 in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Depreciation and Depletion are $121000.0 (Q4 2025), $27000.0 (Q3 2025), and $13000.0 (Q2 2025).